Monobactam
Monobactam is a type of antibiotic that is structurally different from other antibiotics. It is a beta-lactam antibiotic that is resistant to beta-lactamase, an enzyme produced by certain bacteria that can inactivate other beta-lactam antibiotics. Monobactam antibiotics are used to treat infections caused by Gram-negative bacteria, including Pseudomonas aeruginosa and Enterobacteriaceae.
History[edit | edit source]
Monobactams were first discovered in the 1970s in the soil bacterium Chromobacterium violaceum. The first monobactam antibiotic to be developed for clinical use was Aztreonam, which was approved by the Food and Drug Administration (FDA) in 1986.
Structure and Mechanism of Action[edit | edit source]
Monobactams have a unique monocyclic beta-lactam structure, which is different from the bicyclic structure of other beta-lactam antibiotics such as penicillins and cephalosporins. This unique structure makes monobactams resistant to beta-lactamase enzymes.
Monobactams work by inhibiting the synthesis of the bacterial cell wall, leading to cell death. They bind to penicillin-binding proteins (PBPs) in the bacterial cell wall, preventing the cross-linking of peptidoglycan chains, which are essential for bacterial cell wall strength and rigidity.
Clinical Use[edit | edit source]
Monobactams are primarily used to treat infections caused by Gram-negative bacteria, including Pseudomonas aeruginosa and Enterobacteriaceae. They are particularly useful in treating infections in patients who are allergic to other beta-lactam antibiotics, as they do not cross-react with these antibiotics.
Side Effects and Contraindications[edit | edit source]
Common side effects of monobactams include gastrointestinal disturbances, skin rashes, and hypersensitivity reactions. They are contraindicated in patients with a known hypersensitivity to monobactams.
Resistance[edit | edit source]
Resistance to monobactams can occur through several mechanisms, including the production of beta-lactamase enzymes that can inactivate the antibiotic, alterations in PBPs, and changes in the permeability of the bacterial cell wall.
| This article is a stub. You can help WikiMD by registering to expand it. |
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
